Bionano Genomics, Inc. announced that it has entered into an original equipment manufacturing (OEM) partnership agreement with Diagens. Through the partnership, the companies plan to commercialize the first ever cytogenetic workflow using OGM plus AI chromosome karyotype analysis to detect pathogenic SVs associated with recurrent pregnancy loss and other significant genome variants that may impact a pregnancy or lead to developmental issues in a newborn. Diagens has received Class I registration and approval for Bionano's OGM reagents from China's NMPA and will register the Saphyr instrument with NMPA for clinical use in reproductive health.